Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What&rsquo;s new?

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 44

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

363

HTML

3394

Figures (1-1)

194

Tables (1-4)

178

Sum=4129

Nov 28, 2007 (publication date) through Nov 24, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Nov 28, 2007; 13(44): 5877-5887
Published online Nov 28, 2007. doi: 10.3748/wjg.v13.i44.5877

Table 3 Cetuximab as frontline, Phase III studies

C225 plus:	Pts (n)	RR (%)	PFS (mo)	OS (mo)
FOLFOX Cetuximab vs FOLFOX[28]	337	46.6% vs 35.5%	-	-
FOLFIRI Cetuximab vs FOLFIRI[27]	1217	46.9% vs 38.7%	8.9 vs 8.0	-

Pts: Patients; RR: Response rate; PFS: Progression free survival; OS: Overall survival.

Citation: Ponz-Sarvisé M, Rodríguez J, Viudez A, Chopitea A, Calvo A, García-Foncillas J, Gil-Bazo I. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What’s new? World J Gastroenterol 2007; 13(44): 5877-5887
URL: https://www.wjgnet.com/1007-9327/full/v13/i44/5877.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i44.5877